Evofem Biosciences. has been granted a patent for a dual-purpose contraceptive microbicide that prevents pregnancy and reduces sexually transmitted disease risk. The composition includes a matrix-forming compound, a bioadhesive, L-lactic acid, and an aqueous carrier, adapting its state upon contact with ejaculate. GlobalData’s report on Evofem Biosciences gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Evofem Biosciences, Nanoparticle drug conjugates was a key innovation area identified from patents. Evofem Biosciences's grant share as of June 2024 was 42%. Grant share is based on the ratio of number of grants to total number of patents.
The granted patent US11992472B2 outlines a novel method for preventing pregnancy through the intravaginal administration of a specific composition. This composition includes a matrix-forming compound (such as alginic acid, chitosan, gellan gum, or poloxamer), a bioadhesive compound (which may be the same or different from the matrix-forming compound), L-lactic acid, and an aqueous-based pharmaceutically acceptable carrier. Notably, the composition transitions from a nonmatrix state when not in contact with ejaculate to a matrix state upon contact, effectively trapping and inactivating sperm. The formulation is designed to maintain a vaginal pH of 5.0 or below, which is crucial for its efficacy.
Further claims detail the composition's additional components, including humectants (like glycerol or polyethylene glycol) and preservatives (such as benzoic acid or methylparaben). The patent specifies the proportions of these ingredients, recommending a concentration of 1-10% for the matrix-forming and bioadhesive compounds, and 1-7% for L-lactic acid. The preferred matrix-forming compound is alginic acid with a molecular weight between 20,000 to 300,000 g/mole, while xanthan gum is highlighted as a potential bioadhesive. The administration dosage is suggested to be between 1 to 10 grams, with a more specific range of 4 to 6 grams being optimal. This innovative approach aims to provide an effective, localized method of contraception.
To know more about GlobalData’s detailed insights on Evofem Biosciences, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
